Sex-Based Differences in Human Immunodeficiency Virus Type 1 Reservoir Activity and Residual Immune Activation

Plasma human immunodeficiency virus type 1 (HIV-1) RNA levels in women are lower early in untreated HIV-1 infection compared with those in men, but women have higher T-cell activation and faster disease progression when adjusted for viral load. It is not known whether these sex differences persist during effective antiretroviral therapy (ART), or whether they would be relevant for the evaluation and implementation of HIV-1 cure strategies. We prospectively enrolled a cohort of reproductive-aged women and matched men on suppressive ART and measured markers of HIV-1 persistence, residual virus activity, and immune activation. The frequency of CD4+ T cells harboring HIV-1 DNA was comparable between the sexes, but there was higher cell-associated HIV-1 RNA, higher plasma HIV-1 (single copy assay), and higher T-cell activation and PD-1 expression in men compared with women. These sex-related differences in immune phenotype and HIV-1 persistence on ART have significant implications for the design and measurement of curative interventions.

[1]  J. Karn,et al.  Estrogen receptor-1 is a key regulator of HIV-1 latency that imparts gender-specific restrictions on the latent reservoir , 2018, Proceedings of the National Academy of Sciences.

[2]  E. Scully Sex Differences in HIV Infection , 2018, Current HIV/AIDS Reports.

[3]  D. Asmuth,et al.  Sex-Related Differences in Inflammatory and Immune Activation Markers Before and After Combined Antiretroviral Therapy Initiation , 2016, Journal of acquired immune deficiency syndromes.

[4]  Xuerui Tan,et al.  Difference in Leukocyte Composition between Women before and after Menopausal Age, and Distinct Sexual Dimorphism , 2016, PloS one.

[5]  S. Klein,et al.  Sex differences in immune responses , 2016, Nature Reviews Immunology.

[6]  S. Lewin,et al.  Persistence of integrated HIV DNA in CXCR3 + CCR6 + memory CD4+ T cells in HIV-infected individuals on antiretroviral therapy , 2016, AIDS.

[7]  Jerome H. Kim,et al.  Sex differences in soluble markers vary before and after the initiation of antiretroviral therapy in chronically HIV-infected individuals , 2016, AIDS.

[8]  R. Dummer,et al.  Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy , 2017, British Journal of Cancer.

[9]  F. Vaida,et al.  Continued Slow Decay of the Residual Plasma Viremia Level in HIV-1-Infected Adults Receiving Long-term Antiretroviral Therapy. , 2016, The Journal of infectious diseases.

[10]  D. Khan,et al.  The Immune System Is a Natural Target for Estrogen Action: Opposing Effects of Estrogen in Two Prototypical Autoimmune Diseases , 2016, Front. Immunol..

[11]  S. Gianella,et al.  Barriers to a cure for HIV in women , 2016, Journal of the International AIDS Society.

[12]  Rebecca Hoh,et al.  Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study. , 2015, The lancet. HIV.

[13]  C. Charpentier,et al.  Levels of intracellular HIV-DNA in patients with suppressive antiretroviral therapy , 2015, AIDS.

[14]  D. Hazuda,et al.  A Novel Assay to Measure the Magnitude of the Inducible Viral Reservoir in HIV-infected Individuals , 2015, EBioMedicine.

[15]  C. Wira,et al.  The role of sex hormones in immune protection of the female reproductive tract , 2015, Nature Reviews Immunology.

[16]  Jeffrey N. Martin,et al.  UC Office of the President Recent Work Title The immunologic effects of mesalamine in treated HIV-infected individuals with incomplete CD 4 + T cell recovery : a randomized crossover trial , 2014 .

[17]  D. Lauffenburger,et al.  Differential Levels of Soluble Inflammatory Markers by Human Immunodeficiency Virus Controller Status and Demographics , 2014, Open forum infectious diseases.

[18]  D. Hazuda,et al.  Activation of HIV Transcription with Short-Course Vorinostat in HIV-Infected Patients on Suppressive Antiretroviral Therapy , 2014, PLoS pathogens.

[19]  Jintanat Ananworanich,et al.  Cross-Clade Ultrasensitive PCR-Based Assays To Measure HIV Persistence in Large-Cohort Studies , 2014, Journal of Virology.

[20]  O. Lambotte,et al.  Potential Role for HIV-Specific CD38−/HLA-DR+ CD8+ T Cells in Viral Suppression and Cytotoxicity in HIV Controllers , 2014, PloS one.

[21]  Ngan H. Lyle,et al.  CCR5 expression is reduced in lymph nodes of HIV type 1-infected women, compared with men, but does not mediate sex-based differences in viral loads. , 2014, The Journal of infectious diseases.

[22]  V. Calvez,et al.  Factors associated with a low HIV reservoir in patients with prolonged suppressive antiretroviral therapy. , 2014, The Journal of antimicrobial chemotherapy.

[23]  E. Fish,et al.  SeXX matters in immunity. , 2014, Trends in immunology.

[24]  Fred A Wright,et al.  Sex differences in the human peripheral blood transcriptome , 2014, BMC Genomics.

[25]  L. Al-Harthi,et al.  17β-Estradiol inhibits HIV-1 by inducing a complex formation between β-catenin and estrogen receptor α on the HIV promoter to suppress HIV transcription. , 2013, Virology.

[26]  M. Altfeld,et al.  Higher expression of several interferon-stimulated genes in HIV-1-infected females after adjusting for the level of viral replication. , 2013, The Journal of infectious diseases.

[27]  P. Chambon,et al.  Estradiol Promotes Functional Responses in Inflammatory and Steady-State Dendritic Cells through Differential Requirement for Activation Function-1 of Estrogen Receptor α , 2013, The Journal of Immunology.

[28]  W. Mccune,et al.  Overexpression of X-linked genes in T cells from women with lupus. , 2013, Journal of autoimmunity.

[29]  L. Steinman,et al.  Peroxisome proliferator-activated receptor (PPAR)α and -γ regulate IFNγ and IL-17A production by human T cells in a sex-specific way , 2012, Proceedings of the National Academy of Sciences.

[30]  J. Merrill,et al.  Sex-specific differences in the relationship between genetic susceptibility, T cell DNA demethylation and lupus flare severity. , 2012, Journal of autoimmunity.

[31]  J. Arnal,et al.  The TLR-mediated response of plasmacytoid dendritic cells is positively regulated by estradiol in vivo through cell-intrinsic estrogen receptor α signaling. , 2012, Blood.

[32]  J. Harley,et al.  Klinefelter’s syndrome (47,XXY) among men with systemic lupus erythematosus , 2011, Acta paediatrica.

[33]  A. Gilman‐Sachs,et al.  Fluctuation of Peripheral Blood T, B, and NK Cells during a Menstrual Cycle of Normal Healthy Women , 2010, The Journal of Immunology.

[34]  M. Altfeld,et al.  Sex differences in the Toll-like receptor–mediated response of plasmacytoid dendritic cells to HIV-1 , 2009, Nature Medicine.

[35]  M. Petri,et al.  Klinefelter's syndrome (47,XXY) in male systemic lupus erythematosus patients: support for the notion of a gene-dose effect from the X chromosome. , 2008, Arthritis and rheumatism.

[36]  P. Narciso,et al.  Sex issues in HIV-1-infected persons during highly active antiretroviral therapy: a systematic review. , 2007, The Journal of antimicrobial chemotherapy.

[37]  R. Greenblatt,et al.  Does patient sex affect human immunodeficiency virus levels? , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[38]  C. Poole,et al.  Gender Difference in HIV RNA Levels: A Meta‐Analysis of Published Studies , 2002, Journal of acquired immune deficiency syndromes.

[39]  M. Takiguchi,et al.  Differentiation of Human CD8+ T Cells from a Memory to Memory/Effector Phenotype1 , 2002, The Journal of Immunology.

[40]  Peter Bacchetti,et al.  Peer review of statistics in medical research: the other problem , 2002, BMJ : British Medical Journal.

[41]  D R Hoover,et al.  Initial plasma HIV-1 RNA levels and progression to AIDS in women and men. , 2001, The New England journal of medicine.

[42]  J. Margolick,et al.  Association of race and gender with HIV-1 RNA levels and immunologic progression. , 2000 .

[43]  P Pezzotti,et al.  Longitudinal human immunodeficiency virus type 1 load in the italian seroconversion study: correlates and temporal trends of virus load. , 1999, The Journal of infectious diseases.

[44]  J. Margolick,et al.  Sex differences in longitudinal human immunodeficiency virus type 1 RNA levels among seroconverters. , 1999, The Journal of infectious diseases.

[45]  J. Margolick,et al.  Sex differences in HIV-1 viral load and progression to AIDS , 1998, The Lancet.

[46]  T. Perneger What's wrong with Bonferroni adjustments , 1998, BMJ.

[47]  D. Burke,et al.  Serum levels of virus burden in early-stage human immunodeficiency virus type 1 disease in women. , 1997, The Journal of infectious diseases.

[48]  S. Hammer,et al.  The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. , 1996, The New England journal of medicine.

[49]  K J Rothman,et al.  No Adjustments Are Needed for Multiple Comparisons , 1990, Epidemiology.

[50]  M. Heitzeg,et al.  Sex, age, race and intervention type in clinical studies of HIV cure: a systematic review. , 2015, AIDS research and human retroviruses.